Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 9/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 7/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 7/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 7/20 | 0.49 |
| ▸ | BRS3 | P32247 | 3/20 | 0.44 |
| ▸ | ATP4A | P20648 | 3/20 | 0.44 |
| ▸ | ATP4B | P51164 | 3/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179715 | 0.94 | CYP2C9 (0.47) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL29694095 | 0.89 | ATP4A (0.55) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL14433017 | 0.89 | CYP2C9 (0.50) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL537800 | 0.89 | ATP4A (0.55) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL3170408 | 0.88 | ATP4A (0.50) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL3179008 | 0.87 | ATP4A (0.51) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL3170087 | 0.86 | ATP4A (0.50) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL3177079 | 0.84 | ATP4A (0.50) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL9527620 | 0.83 | ATP4A (0.55) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6877051 | 0.83 | BRS3 (0.59) | CYP2C9CYP3A4CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466897-B1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | DIPHARMA FRANCIS SRL (IT) | 2008-12-17 | — | — | EP | claimed |
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2008-06-19 | — | — | US | claimed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | claimed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | claimed |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. | 2004-09-30 | — | — | US | claimed |
| US-20100210846-A1 | Process for preparing 2-(2-pyridylmethyl)-sulfinyl-1H-benzimidazoles and the intermediate compounds used therein | CHEMO IBERICA S.A. (ES) | 2010-08-19 | — | — | US | disclosed |
| US-20100210846-A1 | Process for preparing 2-(2-pyridylmethyl)-sulfinyl-1H-benzimidazoles and the intermediate compounds used therein | CHEMO IBERICA S.A. (ES) | 2010-08-19 | — | — | US | disclosed |
| US-20100022779-A1 | Isotopically substituted proton pump inhibitors | NYCOMED GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100010047-A1 | Isotopically substituted proton pump inhibitors | TAKEDA GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-7601737-B2 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2009-10-13 | — | — | US | disclosed |
| US-7598273-B2 | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598273-B2 | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2007012651-A1 | ISOTOPICALLY SUBSTITUTED PANTOPRAZOLE | NYCOMED GMBH (DE) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012650-A1 | ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS | NYCOMED GMBH (DE) | 2007-02-01 | — | — | WO | disclosed |
| US-7081534-B2 | Process for the preparation of pantoprazole and salts thereof | DIPHARMA S.P.A. (IT) | 2006-07-25 | — | — | US | disclosed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | disclosed |
| US-20050096352-A1 | Process for the preparation of pantoprazole and salts thereof | DIPHARMA S.P.A. (IT) | 2005-05-05 | — | — | US | disclosed |
| EP-1518857-A1 | A process for the preparation of pantoprazole and salts thereof | Dipharma S.p.A. (IT) | 2005-03-30 | — | — | EP | disclosed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | disclosed |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022779-A1 | Isotopically substituted proton pump inhibitors | SLC10A2, ABCB11, SLC10A1 | CYP2C9 100/4885CYP3A4 103/4885CYP2D6 28/4885 |
| US-20100210846-A1 | Process for preparing 2-(2-pyridylmethyl)-sulfinyl-1H-benzimidazoles and the intermediate compounds used therein | SI, SQOR, TPMT | CYP2C9 51/4885CYP3A4 15/4885CYP2D6 42/4885 |
| US-20050096352-A1 | Process for the preparation of pantoprazole and salts thereof | PPOX, MLN, PNPO | CYP2C9 16/4885CYP3A4 8/4885CYP2D6 46/4885 |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | STS, MPST, SULT2A1 | CYP2C9 44/4885CYP3A4 92/4885CYP2D6 155/4885 |
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | SLC10A2, CYP2J2, CYP2D6 | CYP2C9 81/4885CYP3A4 18/4885CYP2D6 3/4885 |
| US-20100010047-A1 | Isotopically substituted proton pump inhibitors | SLC10A2, ABCB11, SLC10A1 | CYP2C9 100/4885CYP3A4 103/4885CYP2D6 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.